Negative regulation of wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3231-3236

  Leach, Steven D ^a,c   Scatena, Caroline D ^b   Keefer, Christopher J ^b   Goodman, Holly A ^a   Song, Si Young ^a   Yang, Liying ^a   Pietenpol, Jennifer A ^b,d  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DEPHOSPHORYLATION; DNA DAMAGE; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN B; DOWN-REGULATION; EMBRYO; ENZYME ACTIVATION; FIBROBLASTS; G2 PHASE; LYMPHOMA, T-CELL; MICE; NOCODAZOLE; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; RATS; TRANSFORMATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032145479     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
2. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
3. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675-684, 1995.
4. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
5. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8493-8497, 1995.
6. Stewart, N., Hicks, G. G., Praskevas, F., and Mowat, M. Evidence for a second cell cycle block at G2/M by p53. Oncogene, 10: 109-115, 1995.
7. 2 to M transition: implications for gene therapy. Cancer Res., 57: 818-823, 1997.
8. Guillouf, C., Rosselli, F., Krishnaraju, K., Moustacchi, E., Hoffman, B., and Liebermann, D. A. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene, 10: 2263-2270, 1995.
9. Gould, K. L., and Nurse, P. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. Nature (Lond.), 342: 39-45, 1989.
10. cdc2 kinase activation in vertebrates. EMBO J., 10: 3331-3341, 1991.
11. Sadhu, K., Reed, S. I., Richardson, H., and Russell, P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Genetics, 87: 5139-5143, 1990.
12. McGowan, C. H., and Russell, P. Cell cycle regulation of human WEE1. EMBO J., 14: 2166-2175, 1995.
13. Watanabe, N., Broome, M., and Hunter, T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J., 14: 1878-1891, 1995.
14. Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M., and Beach, D. Mik1 and Wee1 cooperate in the inhibitory tyrosine phosphorylation of Cdc2. Cell, 64: 1111-1122, 1991.
15. Liu, F., Stanton, J. J., Wu, Z., and Piwnica-Worms, H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell. Biol., 17: 561-583, 1997.
16. Rhind, N., Furnari, B., and Russell, P. Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. Genes Dev., 11: 504-511, 1997.
17. 2 DNA damage checkpoint inhibiting Cdc2 by Y15 phosphorylation. EMBO J., 16: 545-554, 1997.
18. Rowley, R., Hudson, J., and Young, P. G. The Wee1 protein kinase is required for radiation-induced mitotic delay. Nature (Lond.), 356: 353-355, 1992.
19. Barth, H., Hoffmann, I., and Kinzel, V. Radiation with 1 Gy prevents the activation of the mitotic inducers mitosis-promoting factor (MPF) and cdc25-C in HeLa cells. Cancer Res., 56: 2268-2272, 1996.
20. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
21. Wang, Y., Ramqvist, T., Szekely, L., Axelson, H., Klein, G., and Wiman, K. G. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ., 4: 467-473, 1993.
22. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
23. Pietenpol, J. A., Lengauer, C., Jordan, J., Kinzler, K. W., and Vogelstein, B. Mammalian cells resistant to tumor suppressor genes. Proc. Natl. Acad. Sci. USA, 93: 8390-8394, 1996.
24. 1 arrest. Cancer Res., 58: 396-401, 1998.
25. Lanni, J. S., and Jack, T. S. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18: 1055-1064, 1998.
26. Miyashita, T., Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994.
27. Wang, Q., Zambetti, G. P., and Suttle, D. P. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol. Cell. Biol., 17: 389-397, 1997.
28. Murphy, M., Hinman, A., and Levine, A. J. Wild-type p53 negatively regulates expression of a microtubule-associated protein. Genes Dev., 10: 2971-2980, 1996.
29. Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA, 88: 9979-9983, 1991.
30. Seto, E. A., Usheva, G. P., Zambetti, J., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 89: 12028-12032, 1992.
31. Subler, M. A., Martin, D. W., and Deb, S. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol., 66: 4757-4762, 1992.
32. 2 checkpoint pathways in Schizosaccharomyces pombe. EMBO J., 11: 1343-1350, 1992.
33. cdc2 activation required for apoptosis. Science (Washington DC), 263: 1143-1145, 1994.
34. Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55: 228-231, 1995.
35. Fotedar, R., Flatt, J., Gupta, S., Margolis, R. L., Fitzgerald, P., Messier, H., and Fotedar, A. Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B. Mol. Cell. Biol., 15: 932-942, 1995.
36. cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1β-converting enzyme-related proteases. Cancer Res., 56: 4551-4555, 1996.
37. 2-M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86: 1148-1158, 1995.
38. Lin, H. J. L., Eviner, V., Prendergast, G. C., and White, E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol., 15: 4536-4544, 1995.
39. Nishii, K., Kabarowski, J. H., Gibbons, D. L., Griffiths, S. D., Titley, I., Wiedemann, L. M., and Greaves, M. F. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene, 13: 2225-2234, 1996.
40. Chen, G., Shi, L., Litchfield, D. W., and Greenberg, A. H. Rescue from Granzyme B-induced apoptosis by Wee1 kinase. J. Exp. Med., 181: 2295-2300, 1995.
41. Blasina, A., Paegle, E. S., and McGowan, C. H. The role of inhibitory phosphorylation of Cdc2 following DNA replication block and radiation-induced damage in human cells. Mol. Biol. Cell. 8: 1013-1023, 1997.
42. Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., and O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
43. Lock, R. B., Galperina, O. V., Feldhoff, R. C., and Rhodes, L. J. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res., 54: 4933-4939, 1994.